BUZZ-U.S. STOCKS ON THE MOVE-Macerich, Coherus, EveryWare Global

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stocks dipped at the open on Wednesday as a weaker-than-expected report on private sector employment raised concerns that Friday's impending jobs report could also point to worsening conditions in the labor market.

The Dow Jones industrial average was down 0.84 percent at 17,626.58, the S&P 500 was down 0.73 percent at 2,052.8 and the Nasdaq Composite was down 0.93 percent at 4,855.35.

** COHERUS BIOSCIENCES INC (NasdaqGM: CHRS - news) , $27.66, -9.55 pct

The biotech company priced its offering of 4.1 million shares at $29 each, a 5 pct discount to stock's Tuesday close. The upsized $120 million offering represents 12 percent of the company's outstanding shares as of Feb. 28.

** AMERICAN AIRLINES GROUP INC, $50.74, -3.87 pct

** DELTA AIR LINES INC (NYSE: DAL - news) , $43.115, -4.10 pct

** UNITED CONTINENTAL HOLDINGS INC, $64.99, -3.36 pct

Analysts at Deutsche Bank (LSE: 0H7D.L - news) cut ratings on airlines' stocks to "hold" from "buy", saying they expect disappointing earnings growth from international markets. The combination of a strong US dollar, greater-than-expected capacity increases by non-US airlines, and decelerating global GDP growth are likely to further pressure Deutsche Bank's forecast (from international markets) for 2015, analysts write in a note.

** MACERICH CO, $80, -5.13 pct

** SIMON PROPERTY GROUP INC, $196.11, +0.24 pct

Simon Property Group scrapped its attempt to buy Macerich after the smaller shopping mall owner rejected its sweetened offer of $23.2 billion including debt. Macerich Chief Executive Arthur Coppola said the company's board concluded that the offer did not reflect the full value of the company.

** GLAXOSMITHKLINE PLC (Other OTC: GLAXF - news) , $46.35, +0.43 pct

** MERCK (Swiss: MER.SW - news) & CO INC, $56.42, -1.84 pct

Cowen & Co analysts said the drugmaker's vaccine to treat shingles may be more effective than Merck (LSE: 0O14.L - news) 's. Glaxo's vaccine HZ/su should be well positioned to capture market share from Merck's Zostavax if final data from a late-stage study shows HZ/su has better efficacy while treating older patients, analysts said.

** NUVASIVE INC (NasdaqGS: NUVA - news) , $45.09, -1.96 pct

The medical device maker said its chief executive of 16 years Alex Lukianov had resigned after an independent investigation showed he had not complied with the medical device maker's expense reimbursement and personnel policies. The amounts involved appeared immaterial to financial results, the company said. NuVasive has appointed board member Greg Lucier as interim CEO.

** EVERYWARE GLOBAL INC (NasdaqGM: EVRY - news) , $0.21, -82.50 pct

The marketer of tabletop and food preparation products said it expects to file for prepackaged bankruptcy that will give its secured lenders control of the company after it emerges from the bankruptcy. EveryWare said it expects to file for a prepackaged Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware and expects to emerge from bankruptcy within 60-75 days.

** DYAX CORP (NasdaqGM: DYAX - news) , $25.19, +50.34 pct

The drug developer said its experimental drug, DX-2930, to prevent hereditary angioedema attacks, was found effective in an early stage study. The drug was also assigned fast-track status by the U.S. FDA. All seven analysts covering the stock raised price targets, saying the strong results show the drug could eclipse the current standard-of-care preventive treatment for HAE.

** UTI WORLDWIDE INC (NasdaqGS: UTIW - news) , $10.355, -15.81 pct

The logistics company reported a wider-than-expected fourth-quarter loss, hurt by lower air and ocean freight forwarding yields and lower volumes in freight forwarding. The company also cuts its 2016 adjusted EBITDA forecast to $125 million-$150 million from $190 million-$210 million and said revenue would be hurt by the strengthening of the dollar. Morgan Stanley cuts price target by $2.50 to $10, now the lowest on Wall Street.

** SYNNEX CORP (NYSE: SNX - news) , $74.57, -3.47 pct

The hardware distributor forecast second-quarter revenue and adjusted profit below analysts' average estimates, saying revenue is expected to be lowered by about $130 million due to the stronger dollar. The company on Tuesday also reported lower-than-expected first-quarter profit and revenue.

** SEARS HOLDINGS CORP, $45.2613, +9.38 pct

The struggling retailer said it would raise more than $2.5 billion by selling stores to a real estate investment trust it is setting up, in the latest move to shore up its finances. The company would set up a REIT, Seritage Growth Properties, which will buy and lease back about 254 Sears and Kmart stores. Sears will also form a joint venture with mall operator General Growth Properties under which it will sell 12 stores to the JV for a 50 percent stake and $165 million in cash.

** VOLTARI CORP, $2.73, +170.30 pct

Billionaire investor Carl Icahn raises his stake in the digital advertising company to 52.3 percent. Icahn bought about 4 million Voltari shares at $1.36 each via a rights offering.

** MYLAN NV, $57.775, -2.65 pct

** ABBOTT LABORATORIES (Xetra: 850103 - news) , $45.86, -1.01 pct

The generic drug maker priced an offering of 35 million shares at $58.35 per share, a discount of about 2 percent to the stock's Tuesday close. All shares in the offering are to be sold by Abbott Laboratories for net proceeds of about $1.99 billion.

** CARPENTER TECHNOLOGY CORP (NYSE: CRS - news) , $37.179, -4.38 pct

The alloys maker said on Tuesday that it will cut about 10 percent of its salaried workforce, or 200 jobs, to reduce costs amid weak oil and gas prices. The company will also cut about 60 outsourced positions.

** SAREPTA THERAPEUTICS INC (NasdaqGS: SRPT - news) , $13.91, +4.74 pct

The drug developer appointed Chief Medical Officer Edward Kaye as interim CEO, replacing Christopher Garabedian, who resigned. Sarepta is also expected to meet with the FDA over the coming weeks to finalize an application to market its lead drug, eteplirsen, which is designed to attack the underlying cause of Duchenne muscular dystrophy (DMD), a progressive muscle wasting disorder.

** CYTOSORBENTS CORP, $8.95, -32.15 pct

The medical device maker said it expects first-quarter sales to be slightly lower than they were in the fourth-quarter as restructuring of its direct sales force created a significant gap in sales coverage and resulted in lower direct sales.

** CHESAPEAKE ENERGY CORP, $14.53, +2.61 pct

The oil and gas producer's Chairman Dunham Archie bought 1 million shares at $13.98 per share on March 27, according to a regulatory filing on Tuesday. The purchase price represents a 1.3 percent discount to the stock's Tuesday close. After the purchase, Archie holds 2.6 million shares of the company.

** GODADDY INC

The web hosting company has priced its initial public offering at $20 per share, above its previously indicated $17 to $19 per share range, valuing it at around $4.5 billion, including debt, according to underwriting sources. GoDaddy's shares are expected to start trading on Wednesday and list on the New York Stock Exchange under the symbol "GDDY." (Compiled by Ramkumar Iyer in Bengaluru; Editing by Simon Jennings)